Ultragenyx Pharmaceu (RARE)

$26.84 +0.54 (2.05%)
Market Cap 2.59B
Revenue (ttm) 673.00M
Net Income (ttm) -575.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -85.44%
Debt to Equity Ratio 0.00
Volume 1,265,700
Avg Vol 1,972,456
Day's Range N/A - N/A
Shares Out 98.49M
Stochastic %K 82%
Beta 0.39
Analysts Strong Sell
Price Target $52.80

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
SirBioAlot
SirBioAlot May. 13 at 9:37 AM
$RARE still in
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:47 PM
$RARE Current Stock Price: $27.29 Contracts to trade: $27.5 RARE May 15 2026 Call Entry: $0.25 Exit: $0.42 ROI: 69% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JFais
JFais May. 10 at 10:32 PM
$HROW also reporting tomorrow, decent chance of "sell the news" reaction given soft guidance ($30 or even high $20's in such a scenario) Good news is steady improvement toward back half of the year is expected Rationale at the time= Portfolio Cagematch (scooped up $RARE $19's)
2 · Reply
JFais
JFais May. 9 at 6:18 PM
$RARE (L), $MREO (NP) The curious case of setrusumab... per Q1 call:
0 · Reply
mikesterz7
mikesterz7 May. 9 at 1:03 PM
$RARE Ultragenyx trades on a P/S multiple of 3.8x compared with 10.8x for the broader US biotechs group and 20.6x for peers, so on trailing sales the stock has been priced more conservatively than much of its sector.
0 · Reply
JFais
JFais May. 9 at 12:34 PM
$RARE (L) From Weekly Recap
0 · Reply
JFais
JFais May. 9 at 12:24 PM
$RARE (L) From Weekly Recap
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels May. 7 at 12:05 PM
$RARE $SRPT RARE is back under $30? Need to research but that’s always been a good buy zone for a medium term trade.
0 · Reply
murphylaw
murphylaw May. 7 at 11:53 AM
$SRPT volume is only 106k today. Wait until market opens. Same happened with $RARE yesterday.
2 · Reply
Merlintrader
Merlintrader May. 7 at 5:36 AM
$RARE Ultragenyx Pharmaceutical Inc. (Nasdaq: $RARE): May 2026 Deep Dive https://www.merlintrader.com/ultragenyx-pharmaceuticals-inc-may2026-deepdive/
0 · Reply
Latest News on RARE
Ultragenyx Pharmaceutical Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 5:20 PM EDT - 16 hours ago

Ultragenyx Pharmaceutical Transcript: Bank of America Global Healthcare Conference 2026

Ultragenyx price target lowered to $33 from $34 at Evercore ISI

2026-05-11T16:15:56.000Z - 1 day ago

Ultragenyx price target lowered to $33 from $34 at Evercore ISI

Ultragenyx price target lowered to $26 from $27 at Wedbush

2026-05-08T13:52:56.000Z - 5 days ago

Ultragenyx price target lowered to $26 from $27 at Wedbush

Ultragenyx price target lowered to $43 from $52 at Guggenheim

2026-05-08T13:31:39.000Z - 5 days ago

Ultragenyx price target lowered to $43 from $52 at Guggenheim

Rare disease families find roadmap to drug development at bootcamps.

May 7, 2026, 4:00 PM EDT - 5 days ago

Rare disease families find roadmap to drug development at bootcamps.

Rare disease families find roadmap to drug development at bootcamps

May 7, 2026, 6:30 AM EDT - 6 days ago

Rare disease families find roadmap to drug development at bootcamps

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

May 6, 2026, 4:30 PM EDT - 6 days ago

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026

May 5, 2026, 5:00 PM EDT - 7 days ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

May 5, 2026, 4:01 PM EDT - 7 days ago

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Apr 29, 2026, 8:00 AM EDT - 14 days ago

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Ultragenyx price target lowered to $43 from $44 at Barclays

2026-04-29T09:45:53.000Z - 14 days ago

Ultragenyx price target lowered to $43 from $44 at Barclays

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 24, 2026, 4:30 PM EDT - 18 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx price target raised to $67 from $50 at Morgan Stanley

2026-04-16T12:35:15.000Z - 27 days ago

Ultragenyx price target raised to $67 from $50 at Morgan Stanley

DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

Apr 3, 2026, 9:43 AM EDT - 5 weeks ago

DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

Ultragenyx UX111 AAV9 biologics license application accepted for FDA review

2026-04-02T13:06:11.000Z - 5 weeks ago

Ultragenyx UX111 AAV9 biologics license application accepted for FDA review

Ultragenyx announces FDA clearance of UX016 investigational new drug application

2026-03-30T13:27:59.000Z - 6 weeks ago

Ultragenyx announces FDA clearance of UX016 investigational new drug application

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Mar 30, 2026, 8:30 AM EDT - 6 weeks ago

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Ultragenyx downgraded to Neutral from Buy at Goldman Sachs

2026-03-24T08:35:19.000Z - 7 weeks ago

Ultragenyx downgraded to Neutral from Buy at Goldman Sachs

Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims

2026-03-18T15:57:48.000Z - 7 weeks ago

Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Mar 12, 2026, 8:47 AM EDT - 2 months ago

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Ultragenyx Phase 3 Enh3ance study showed statistically significant results

2026-03-12T12:36:18.000Z - 2 months ago

Ultragenyx Phase 3 Enh3ance study showed statistically significant results

Ultragenyx price target lowered to $74 from $120 at JPMorgan

2026-03-12T10:54:43.000Z - 2 months ago

Ultragenyx price target lowered to $74 from $120 at JPMorgan

Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 11:00 AM EDT - 2 months ago

Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026

Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 12:00 PM EDT - 2 months ago

Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference

Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:50 PM EST - 2 months ago

Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 24, 2026, 9:11 AM EST - 2 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Ultragenyx to Participate at Investor Conferences in March

Feb 23, 2026, 4:30 PM EST - 2 months ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx announces U.S. FDA accepted for review BLA for DTX401 AAV

2026-02-23T13:42:16.000Z - 2 months ago

Ultragenyx announces U.S. FDA accepted for review BLA for DTX401 AAV

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Feb 23, 2026, 8:30 AM EST - 2 months ago

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Feb 18, 2026, 2:07 PM EST - 2 months ago

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Ultragenyx price target lowered to $34 from $37 at Evercore ISI

2026-02-18T13:20:39.000Z - 3 months ago

Ultragenyx price target lowered to $34 from $37 at Evercore ISI

Ultragenyx Pharmaceutical Earnings Call Transcript: Q4 2025

Feb 12, 2026, 5:00 PM EST - 3 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q4 2025

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Feb 12, 2026, 4:01 PM EST - 3 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Feb 9, 2026, 3:01 AM EST - 3 months ago

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Feb 3, 2026, 8:00 AM EST - 3 months ago

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Jan 30, 2026, 8:30 AM EST - 3 months ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Jan 23, 2026, 2:05 PM EST - 3 months ago

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Ultragenyx Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 4 months ago

Ultragenyx Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 4 months ago

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Dec 30, 2025, 4:05 PM EST - 4 months ago

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Dec 30, 2025, 2:24 PM EST - 4 months ago

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dec 29, 2025, 1:05 PM EST - 4 months ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

MREO

Ultragenyx's bone disease drug fails late-stage trials

Dec 29, 2025, 8:35 AM EST - 4 months ago

Ultragenyx's bone disease drug fails late-stage trials

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Dec 29, 2025, 8:30 AM EST - 4 months ago

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Ultragenyx Pharmaceutical Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 12:55 PM EST - 5 months ago

Ultragenyx Pharmaceutical Transcript: Evercore ISI 8th Annual HealthCONx Conference

Ultragenyx Pharmaceutical Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 3:15 PM EST - 5 months ago

Ultragenyx Pharmaceutical Transcript: Citi Annual Global Healthcare Conference 2025

Ultragenyx Pharmaceutical Earnings Call Transcript: Q3 2025

Nov 4, 2025, 5:00 PM EST - 6 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q3 2025

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Nov 4, 2025, 4:01 PM EST - 6 months ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 4:30 PM EDT - 7 months ago

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Sep 30, 2025, 4:05 PM EDT - 8 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx to Participate at Investor Conferences in September

Aug 29, 2025, 4:30 PM EDT - 9 months ago

Ultragenyx to Participate at Investor Conferences in September

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Aug 18, 2025, 8:00 AM EDT - 9 months ago

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Earnings Call Transcript: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 10 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q2 2025

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 5, 2025, 4:01 PM EDT - 10 months ago

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Jul 30, 2025, 8:30 AM EDT - 10 months ago

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

SirBioAlot
SirBioAlot May. 13 at 9:37 AM
$RARE still in
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:47 PM
$RARE Current Stock Price: $27.29 Contracts to trade: $27.5 RARE May 15 2026 Call Entry: $0.25 Exit: $0.42 ROI: 69% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JFais
JFais May. 10 at 10:32 PM
$HROW also reporting tomorrow, decent chance of "sell the news" reaction given soft guidance ($30 or even high $20's in such a scenario) Good news is steady improvement toward back half of the year is expected Rationale at the time= Portfolio Cagematch (scooped up $RARE $19's)
2 · Reply
JFais
JFais May. 9 at 6:18 PM
$RARE (L), $MREO (NP) The curious case of setrusumab... per Q1 call:
0 · Reply
mikesterz7
mikesterz7 May. 9 at 1:03 PM
$RARE Ultragenyx trades on a P/S multiple of 3.8x compared with 10.8x for the broader US biotechs group and 20.6x for peers, so on trailing sales the stock has been priced more conservatively than much of its sector.
0 · Reply
JFais
JFais May. 9 at 12:34 PM
$RARE (L) From Weekly Recap
0 · Reply
JFais
JFais May. 9 at 12:24 PM
$RARE (L) From Weekly Recap
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels May. 7 at 12:05 PM
$RARE $SRPT RARE is back under $30? Need to research but that’s always been a good buy zone for a medium term trade.
0 · Reply
murphylaw
murphylaw May. 7 at 11:53 AM
$SRPT volume is only 106k today. Wait until market opens. Same happened with $RARE yesterday.
2 · Reply
Merlintrader
Merlintrader May. 7 at 5:36 AM
$RARE Ultragenyx Pharmaceutical Inc. (Nasdaq: $RARE): May 2026 Deep Dive https://www.merlintrader.com/ultragenyx-pharmaceuticals-inc-may2026-deepdive/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:12 PM
$RARE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.84 down -17.20% YoY • Reported revenue of $136M down -2.36% YoY • Ultragenyx reaffirms full year 2026 total revenue guidance of $730M to $760M. Ultragenyx expects combined R&D and SG&A expenses to be flat to slightly down versus 2025, on path to profitability in 2027.
1 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ May. 5 at 8:08 PM
$RARE hmmmm it’s a miss
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS May. 5 at 12:12 PM
$RARE mmmmmm I see you
0 · Reply
Pharma3000
Pharma3000 May. 5 at 11:40 AM
$RARE
1 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 9:29 PM
$RARE Share Price: $24.81 Contract Selected: Nov 20, 2026 $25 Calls Buy Zone: $4.76 – $5.88 Target Zone: $8.82 – $10.78 Potential Upside: 75% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StockConsultant
StockConsultant May. 4 at 12:50 PM
$RARE Ultragenyx Pharmaceutical stock, watch for an upside gap breakout at https://stockconsultant.com/?RARE
0 · Reply
Teamtalk2014
Teamtalk2014 May. 1 at 6:56 PM
$MREO Massive undervaluation. $RARE Likely to proceed with UX143, would have been dropped by now if they could not see a path forward. Expecting news on next steps soon. Would not be short.
1 · Reply
LaGoodie
LaGoodie Apr. 28 at 5:41 PM
$RARE
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 23 at 4:49 AM
$RARE RSI: 70.85, MACD: 0.8382 Vol: 1.98, MA20: 22.81, MA50: 22.23 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
shortvolume
shortvolume Apr. 17 at 11:44 PM
$RARE unintelligent bears short while our algorithm signals alpha.
0 · Reply
Biologics
Biologics Apr. 12 at 12:59 PM
My recent article on $RARE https://seekingalpha.com/article/4890075-ultragenyx-pharmaceutical-the-market-is-overlooking-2026-catalysts?source=copy_to_clipboard
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 9 at 8:36 PM
$RARE Phase 3 Enh3ance hits primary endpoint: 18% ammonia reduction vs placebo (p=0.018) with 27% scavenger taper. One placebo death, zero treated. 64-week treatment burden data H1 2027 — that's the BLA readout. Pricing at $2.5-3.2M justified against $500K-1M/yr Ravicti. TAM ~250-300 patients limits peak revenue but PRV ($95-110M) de-risks near-term. Read more: www.clinicaltrialsdaily.com/ultragenyx-dtx301-phase-3-otc-deficiency/
0 · Reply